Abstract
Beta2-adrenergic receptor (β2AR) agonists can have protective effects targeting macrophage activation, but research on human subjects has not been done. This study was designed to assess the relationship between the use of β2AR agonists and diabetic vascular complications. Using data from the Korean National Health Insurance Service, adults first diagnosed with diabetes in 2004 (n = 249,222) were followed up until 31 December 2015. Propensity score matching was performed between case and control groups (n = 5179 in each), and multivariate analysis was conducted. The β2AR agonist group was divided into quartiles according to the duration of β2AR agonist use. During the follow-up, the incidence of vascular complications gradually decreased as the duration of β2AR agonist administration increased. Multivariate analysis revealed that the hazard ratio for all composite vascular complications was 0.80 (95% CI, 0.75-0.86, p < 0.001) in the longest quartile of β2AR agonist use as compared with the control group after adjusting for confounding variables. The association between the duration of β2AR agonist use and the risk of each vascular complication including cerebrovascular, peripheral vascular, peripheral neural, renal, and ophthal...Continue Reading
References
Aug 1, 1998·Diabetologia·J TuomilehtoA Reunanen
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Michael J AbramsonE Haydn Walters
May 28, 2005·Diabetes Care·Manon V van HeckeUNKNOWN EURODIAB prospective complications study
Dec 5, 2006·Life Sciences·Toshio HayashiAkihisa Iguchi
Dec 8, 2007·European Heart Journal·Tim C ClaytonTom W Meade
Nov 14, 2008·Health Policy and Planning·Soonman Kwon
Sep 26, 2009·The Lancet Infectious Diseases·Charlotte Warren-GashAndrew C Hayward
Nov 27, 2009·Diabetes Research and Clinical Practice·Xinglong CuiTomoichiro Asano
Mar 11, 2010·COPD·Cağatay OncelFatma Evyapan
Jul 9, 2010·Lancet·UNKNOWN Emerging Risk Factors CollaborationJ Danesh
Sep 15, 2010·Biochemical and Biophysical Research Communications·Paras Kumar MishraSuresh C Tyagi
Jan 11, 2011·QJM : Monthly Journal of the Association of Physicians·P MandalA T Hill
Jun 18, 2011·Annals of Medicine·Tomohiro Nishizawa, Karin E Bornfeldt
Aug 23, 2011·Respiratory Medicine·Mario CazzolaPaola Rogliani
Feb 1, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Syed Mohamed AljunidLing Xu
Jul 24, 2012·Seminars in Vascular Surgery·Gary W Gibbons, Palma M Shaw
Aug 21, 2012·The Canadian Journal of Cardiology·S F Paul ManDon D Sin
Jun 25, 2014·Inflammation·Zhigang WangHongli Jiang
Aug 7, 2014·Heart·Jack R W BrownriggRobert J Hinchliffe
Dec 3, 2014·European Journal of Pharmacology·A M BarakaH K Korayem
Jan 12, 2016·Kidney & Blood Pressure Research·Sky K H ChewJudy Savige
Dec 3, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·Kazuyuki YahagiRenu Virmani
Apr 8, 2017·International Urology and Nephrology·Min Young KimNa Ree Kang
Apr 12, 2017·Kidney International·Hyunjin NohGeorge L King
Aug 13, 2017·Stroke; a Journal of Cerebral Circulation·Chang-Yun YoonTae-Hyun Yoo
Feb 2, 2018·Diabetes Care·Daniel GordinGeorge L King
Mar 28, 2018·Advances in Chronic Kidney Disease·Digsu N KoyeMeda E Pavkov
Oct 3, 2018·Diabetes Care·Julie A LovshinDavid Z I Cherney